Natalizumab (ITGA4/CD49d) - Research Grid Biosimilar
Gecertificeerd

Natalizumab (ITGA4/CD49d) - Research Grid Biosimilar

Catalog #: 10-090
Maat: 0.1 mg

Kwaliteit

ISO Gecertificeerd

Levering

24-48 uur

Prijs -1%
Login voor prijs
BTW niet inbegrepen
Gratis verzending vanaf €100
Technische Documentatie

Technische Specificaties

Background

Natalizumab is a recombinant, humanized monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1) .Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses.

Swiss Prot

P13612

Immunogen

Humanized / ITGA4/CD49d [Homo sapiens]

Clonality

• Recombinant Monoclonal

Conjugation

Unconjugated

Type

Primary Antibodies, Biosimilars

Source

CHO cells

Field of Research

Neuroscience

Purification

>95%

Concentration

Batch dependent

Buffer

PBS buffer pH7.5

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.

Fragment

IgG4-kappa

NCBI Organism

Homo sapiens

Other Product Names

AN 100226, BG00002, ITGA4/CD49d, ITGA4/CD49d

Beschrijving

Natalizumab (ITGA4/CD49d) - Research Grid Biosimilar Beschikbaar in 0.1 mg. Bestel eenvoudig online met snelle levering.

Specificaties

ProductnaamNatalizumab (ITGA4/CD49d) - Research Grid Biosimilar
Categorie
Beschikbare grootte0.1 mg
Catalogusnummer10-090